fda drug safety communication naion semaglutide 2025 Is Semaglutide Linked to NAION? A Case Report on a Rare Ocular Complication Upcoming FDA Approvals: New Drugs

After 48 weeks, 9 (39%) of the 23 patients who received liraglutide 1.8 mg daily and underwent a follow-up biopsy achieved MASH resolution, compared with only 2 (9%) of 22 patients in the placebo group ( P = .019)

She acquired a local Kenyan name Malaika kubwa ( a Swahili name translating to big angel)

Monitor for diminishing effects, which may indicate the need for reduced frequency or a complete break from DSIP

[44] Semaglutide remains contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2

Treatment begins with 3 mg once daily for 30 days, which is a starter dose to improve tolerability and is not intended for glycaemic control